Supplemental NDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab in 1L PD-L1+ve NSCLC Accepted for Review by NMPA May 12, 2026
FDA cleared IND for Ph 1/2 study of oral elraglusib in metastatic melanoma, NSCLC, colorectal, and pancreatic cancers May 12, 2026
NICE issues Final Draft Guidance recommending RYBREVANT + chemo during managed access period in 1L NSCLC with EGFR ex20ins mutations in adults May 12, 2026
FDA Accepts Supplemental NDA for IBTROZI® (taletrectinib) with Updated DoR in Advanced ROS1+ve NSCLC May 12, 2026
US FDA Accepts NDA for Zipalertinib for the Treatment of Locally Advanced or Metastatic NSCLC with EGFR Exon 20 Insertion Mutations May 6, 2026
Ph 3 STAR-121 study of domvanalimab, zimberelimab and chemo vs pembrolizumab + chemo in 1L NSCLC to be discontinued April 28, 2026
First US Site Activated for Ongoing International Ph 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced NSCLC April 21, 2026
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement April 21, 2026
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Ph 3 Trial of Novel Telomere-Targeting Anticancer Therapy April 15, 2026
Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor–Resistant Advanced NSCLC Presented April 15, 2026
OS beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of Ph 2 THIO-101 trial in NSCLC reported April 7, 2026
ZEGFROVY® (Sunvozertinib) Shows Antitumor Activity in 1L NSCLC Patients with EGFR PACC or Other Uncommon Mutations March 31, 2026
Ph 1/2 Duravelo-3 trial for zelenectide in NECTIN4-amplified breast cancer and Duravelo-4 trial in NECTIN4-amplified NSCLC to be discontinued; trial design of Duravelo-2 trial to be changed March 24, 2026
Positive Ph 3 Results from WU-KONG28 Study of ZEGFROVY® (Sunvozertinib) vs. Chemo in 1L NSCLC with exon20ins Mutation Announced March 24, 2026
First Patient Dosed in Ph 1/2 Trial of TRI-611 for the Treatment of ALK Positive NSCLC March 24, 2026
Extended long-term survival observed in Ph 2a trial in advanced NSCLC treated with aglatimagene besadenovec (aglatimagene or CAN-2409) March 24, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
